ERBB4 and breast cancer: The estimated pooled HRs for these 14 studies revealed that elevated/positive HER4 expression played a more favorable role in the RFS of patients with breast cancer (HR = 0.63; CI: 0.48–0.83; P = 0.001, random effects; Figure 2A).